These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36410086)

  • 1. The impact of single agent PD-1 or PD-L1 inhibition on advanced endometrial cancers: meta-analysis.
    Kok PS; Antill YC; Scott CL; Lee CK
    ESMO Open; 2022 Dec; 7(6):100635. PubMed ID: 36410086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of PD-1/PD-L1 Inhibitor as Single-Agent Immunotherapy in Endometrial Cancer: A Systematic Review and Meta-Analysis.
    Mamat Yusof MN; Chew KT; Hafizz AMHA; Abd Azman SH; Ab Razak WS; Hamizan MR; Kampan NC; Shafiee MN
    Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis.
    Bartoletti M; Montico M; Lorusso D; Mazzeo R; Oaknin A; Musacchio L; Scambia G; Puglisi F; Pignata S
    Cancer Treat Rev; 2024 Apr; 125():102701. PubMed ID: 38422895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of immune-checkpoint inhibitors combined with cytotoxic chemotherapy in advanced or recurrent endometrial cancer: A systematic review and meta-analysis.
    Kim JH; Han KH; Park EY; Kim ET; Kim EJ; Tan DSP; Lee JY; Park SY; Fotopoulou C; Lim MC
    Gynecol Oncol; 2024 Aug; 187():85-91. PubMed ID: 38735144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of PD-1/PD-L1 inhibitors monotherapy in patients with endometrial cancer.
    Wan X; Huang J; Huang L; Wang Y; Fu Y; Jin X; Huang Z; Xiong J
    Discov Oncol; 2024 May; 15(1):168. PubMed ID: 38750182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a systematic review and meta-analysis.
    Han S; Guo C; Song Z; Ouyang L; Wang Y
    Front Pharmacol; 2023; 14():1330877. PubMed ID: 38161705
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial.
    Antill Y; Kok PS; Robledo K; Yip S; Cummins M; Smith D; Spurdle A; Barnes E; Lee YC; Friedlander M; Baron-Hay S; Shannon C; Coward J; Beale P; Goss G; Meniawy T; Lombard J; Andrews J; Stockler MR; Mileshkin L;
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34103352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1/PD-L1 Inhibitors Monotherapy for the Treatment of Endometrial Cancer: Meta-Analysis and Systematic Review.
    Dai Y; Muaibati M; Xie W; Abasi A; Li K; Tong Q; Zhang T; Meng Y; Zhuang L; Huang X
    Cancer Invest; 2022 Mar; 40(3):293-309. PubMed ID: 34825855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment.
    Song Y; Gu Y; Hu X; Wang M; He Q; Li Y
    Onco Targets Ther; 2021; 14():4485-4497. PubMed ID: 34429613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of mismatch repair deficiency in endometrial cancer with
    Sun X; Yao X; Zeng B; Zhu L; Shang Y; Zhang Q; He L; Jiang L
    Ann Nucl Med; 2023 Dec; 37(12):655-664. PubMed ID: 37743402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of PD-1/L1 inhibitors as first-line therapy for metastatic colorectal cancer: a meta-analysis.
    Huang Z; Li C; Huang Y; Liang W; Tao H
    Front Immunol; 2024; 15():1425596. PubMed ID: 39100666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of lenvatinib plus pembrolizumab in patients with advanced and recurrent endometrial cancer: a systematic review and meta-analysis.
    Yan G; Du Y; Zhang H; Yan J; Liu Y; Ban Z; Guo YZ; Zeng X
    Front Immunol; 2024; 15():1404669. PubMed ID: 39185408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
    Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
    Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endometrial Cancer Presentation and Outcomes Based on Mismatch Repair Protein Expression From a Population-Based Study.
    Pina A; Wolber R; McAlpine JN; Gilks B; Kwon JS
    Int J Gynecol Cancer; 2018 Oct; 28(8):1624-1630. PubMed ID: 30095707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes.
    Williams DS; Mouradov D; Jorissen RN; Newman MR; Amini E; Nickless DK; Teague JA; Fang CG; Palmieri M; Parsons MJ; Sakthianandeswaren A; Li S; Ward RL; Hawkins NJ; Faragher I; Jones IT; Gibbs P; Sieber OM
    Gut; 2019 Mar; 68(3):465-474. PubMed ID: 29382774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Programmed Death-Ligand 1 Expression on Mismatch Repair Deficiency and Epstein-Barr Virus Status on Survival Outcomes in Patients with Stage II/III Gastric Cancer After Surgery.
    Akimoto E; Kuwata T; Shitara K; Kawazoe A; Sakamoto N; Ishii G; Ochiai A; Kinoshita T
    Ann Surg Oncol; 2023 Aug; 30(8):5227-5236. PubMed ID: 36934377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deciding the operation type according to mismatch repair status among hereditary nonpolyposis colorectal cancer patients: should a tailored approach be applied, or does one size fit all?
    Liao CK; Lin YC; Hsu YJ; Chern YJ; You JF; Chiang JM
    Hered Cancer Clin Pract; 2021 Jun; 19(1):29. PubMed ID: 34187536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Micro Satellite Instability and Mismatch Repair Status in Different Solid Tumors: A Multicenter Analysis in a Real World Setting.
    Malapelle U; Parente P; Pepe F; De Luca C; Pisapia P; Sgariglia R; Nacchio M; Gragnano G; Russo G; Conticelli F; Bellevicine C; Vigliar E; Iaccarino A; Covelli C; Balistreri M; Clemente C; Perrone G; Danza A; Scaramuzzi F; Fassan M; Troncone G; Graziano P
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic and predictive value of mismatch repair status in patients with locally advanced rectal cancer following neoadjuvant therapy.
    Wu Z; Hu H; Wang C; Zhang J; Cai Y; Xie X; Huang Y; Deng Y
    Ann Transl Med; 2022 Apr; 10(8):491. PubMed ID: 35571401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
    Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
    J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.